기본 통계
| CIK | 1766140 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Unicycive Therapeutics, Inc.
SEC Filings (Chronological Order)
이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40582 UNICYCIVE THERAPEUTI |
|
| May 12, 2026 |
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update Exhibit 99.1 Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update - U.S. Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026 - Commercial readiness activities continue in anticipation of the p |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2026 Unicycive Therapeutics, Inc. |
|
| May 6, 2026 |
As filed with the Securities and Exchange Commission on May 5, 2026 As filed with the Securities and Exchange Commission on May 5, 2026 Registration No. |
|
| May 6, 2026 |
CALCULATION OF FILING FEE TABLES Unicycive Therapeutics Inc. Table 1: Newly Registered Securities Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Unicycive Therapeutics Inc. Table 1: Newly Registered Securities Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per share (1) Other 973,020 $ $ 7,900,922.40 0.0001381 |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40582 UNICYCIVE THERAPEUTICS, INC. |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2026 Unicycive Therapeutics, Inc. |
|
| March 30, 2026 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2025, Unicycive Therapeutics, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (i) common stock, $0.001 par value per share (“Common Stock”). Unless the context otherwi |
|
| March 30, 2026 |
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update Exhibit 99.1 Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update - Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026 - Commercial readiness activities ongoing in anticipation of potential commercial l |
|
| March 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40582 UNICYCIVE THERAPEUTICS, INC. |
|
| March 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2026 Unicycive Therapeutics, Inc. |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 Unicycive Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40582 81-3638692 (State or other jurisdiction of incorporation) (Com |
|
| November 14, 2025 |
Up to $100,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-283210 PROSPECTUS SUPPLEMENT (To Prospectus dated November 20, 2024, as supplemented by Prospectus Supplement dated June 13, 2025) Up to $100,000,000 Common Stock This prospectus supplement (“Prospectus Supplement”) amends and supplements the information in the prospectus supplement dated November 20, 2024, as filed with the Securities and Exch |
|
| November 14, 2025 |
UNICYCIVE THERAPEUTICS, INC. AMENDMENT NO. 1 TO SALES AGREEMENT November 14, 2025 Exhibit 1.1 UNICYCIVE THERAPEUTICS, INC. AMENDMENT NO. 1 TO SALES AGREEMENT November 14, 2025 This Amendment No. 1 (“Amendment No. 1”) amends that certain Sales Agreement, dated as of November 13, 2024 (the “Agreement”), by and between Unicycive Therapeutics, Inc., a Delaware corporation (the “Company”), and Guggenheim Securities, LLC, as sales agent (the “Agent”). Defined terms used herein and no |
|
| November 12, 2025 |
Exhibit 99.1 Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update - Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end - Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates that OLC significantly reduced pill burden in terms of both pill volume (7x) and pill |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40582 UNICYCIVE THERAP |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2025 Unicycive Therapeutics, Inc. |
|
| October 28, 2025 |
Exhibit 99.1 Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End - Cash runway into 2027, which is expected to support application resubmission, potential FDA approval, and launch of OLC LOS ALTOS, California, October 28, 2025 - Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for pat |
|
| October 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2025 Unicycive Therapeutics, Inc. |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 Unicycive Therapeutics, Inc. |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 Unicycive Therapeutics, Inc. |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Unicycive Therapeutics, Inc. |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40582 UNICYCIVE THERAPEUTIC |
|
| August 14, 2025 |
Exhibit 99.1 Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - Type A Meeting requested with U.S. Food and Drug Administration (FDA) for resolution of the Complete Response Letter (CRL) for oxylanthanum carbonate (OLC) - OLC pivotal study data, published in the Clinical Journal of the American Society of Nephrology (CJASN), demonstrated OLC was w |
|
| August 14, 2025 |
Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF CORRECTION Unicycive Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware. DOES HEREBY CERTIFY: 1. The name of the corporation is Unicycive Therapeutics, Inc. 2. That the Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Conve |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 Unicycive Therapeutics, Inc. |
|
| July 8, 2025 |
Exhibit 99.1 Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement -Nasdaq compliance follows reverse stock split previously announced on June 17, 2025 LOS ALTOS, Calif., July 8, 2025 – Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announce |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 Unicycive Therapeutics, Inc. |
|
| June 30, 2025 |
Exhibit 99.1 Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis -Complete Response Letter (CRL) cited deficiencies previously identified at a third-party manufacturing vendor unrelated to Oxylanthanum Carbonate (OLC) -No other concerns stated, including pre-clinic |
|
| June 20, 2025 |
Exhibit 99.1 Unicycive Therapeutics, Inc. Announces Reverse Stock Split Shares Expected to Begin Trading on Split-Adjusted Basis on June 20, 2025 LOS ALTOS, Calif., June 17, 2025 (GLOBE NEWSWIRE) - Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that it will implement a 1-for-10 reverse split |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Unicycive Therapeutics, Inc. |
|
| June 20, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT to the CERTIFICATE OF INCORPORATION of UNICYCIVE THERAPEUTICS, INC. UNICYCIVE THERAPEUTICS, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The name of the Corporation is Unicycive Therapeutics, Inc. The Certificate of Incorporation was filed with t |
|
| June 13, 2025 |
Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-283210 PROSPECTUS SUPPLEMENT (To Prospectus dated November 20, 2024) Up to $50,000,000 Common Stock This prospectus supplement (“Prospectus Supplement”) amends and supplements the information in the prospectus supplement dated November 20, 2024, as filed with the Securities and Exchange Commission on November 13, 2024 (the “ATM Prospectus”), re |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 Unicycive Therapeutics, Inc. |
|
| June 10, 2025 |
Exhibit 99.1 Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - The U.S. Food and Drug Administration (FDA) identified deficiencies at a third-party manufacturing vendor - FDA to provide final decision by PDUFA action date of June 28, 2025 LOS ALTOS, Calif., June 10, 2025 – Unicycive Therapeu |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 Unicycive Therapeutics, Inc. |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 Unicycive Therapeutics, Inc. |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stateme |
|
| May 21, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 Unicycive Therapeutics, Inc. |
|
| May 21, 2025 |
Press Release dated May 21, 2025 Exhibit 99.1 Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders LOS ALTOS, CA May 21, 2025/ Unicycive Therapeutics, Inc. (NASDAQ: UNCY) (“Unicycive” or the “Company”), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced a change in the time of the 2025 Annual Meeting of Stockholders (the “Annual Meeting”). |
|
| May 21, 2025 |
Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders Exhibit 99.1 Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders LOS ALTOS, CA May 21, 2025/ Unicycive Therapeutics, Inc. (NASDAQ: UNCY) (“Unicycive” or the “Company”), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced a change in the time of the 2025 Annual Meeting of Stockholders (the “Annual Meeting”). |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 Unicycive Therapeutics, Inc. |
|
| May 14, 2025 |
Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025 - N |
|
| May 14, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Unicycive Therapeutics, Inc. |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40582 UNICYCIVE THERAPEUTI |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stateme |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40582 UNICYCIVE THERAPEUTICS, INC. |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 14, 2025 |
Form of Amended and Restated Tranche C Warrant Exhibit 4.3 UNICYCIVE THERAPEUTICS, INC. AMENDED AND RESTATED TRANCHE C WARRANT TO PURCHASE SERIES A-5 PREFERRED STOCK Warrant No.: C- Number of Warrant Shares: Date of Issuance: March 13, 2024 (“Issuance Date”) Expiration Date: Twenty-one (21) days following the Company’s public disclosure of financial results for four (4) quarters of commercial sales of Renazorb following receipt of Transitional |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 UNICYCIVE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40582 81-3638692 (State or other jurisdiction of in |
|
| April 14, 2025 |
Form of Amended and Restated Tranche B Warrant Exhibit 4.2 UNICYCIVE THERAPEUTICS, INC. AMENDED AND RESTATED TRANCHE B WARRANT TO PURCHASE SERIES A-4 PREFERRED STOCK Warrant No.: B- Number of Warrant Shares: Date of Issuance: March 13, 2024 (“Issuance Date”) Expiration Date: Twenty-one (21) days following the Company’s announcement of receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb (“Expiration Date”) Unicycive The |
|
| April 1, 2025 |
As filed with the Securities and Exchange Commission on April 1, 2025 As filed with the Securities and Exchange Commission on April 1, 2025 Registration No. |
|
| April 1, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Unicycive Therapeutics, Inc. |
|
| March 31, 2025 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, Unicycive Therapeutics, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (i) common stock, $0.001 par value per share (“Common Stock”). Unless the context otherwi |
|
| March 31, 2025 |
Exhibit 99.1 Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update - Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025 - Commercial Planning in Preparation for anticipated commercial launch of OLC in late 2025 LOS ALT |
|
| March 31, 2025 |
Exhibit 19.1 UNICYCIVE THERAPEUTICS, INC. INSIDER TRADING POLICY This Insider Trading Policy (the “Policy”) provides guidelines to officers, directors, employees (including temporary employees) and other related individuals of Unicycive Therapeutics, Inc. (the “Company”) with respect to transactions in the Company’s securities. The Reasons for an Insider Trading Policy The Federal securities laws |
|
| March 31, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Unicycive Therapeutics, Inc. |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40582 UNICYCIVE THERAPEUTICS, INC. |
|
| February 14, 2025 |
EX-99.1 2 ex-99-02142025110211.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United State |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 Unicycive Therapeutics, Inc. |
|
| November 18, 2024 |
Unicycive Therapeutics, Inc. 4300 El Camino Real, Suite 210 Los Altos, CA 94022 Unicycive Therapeutics, Inc. 4300 El Camino Real, Suite 210 Los Altos, CA 94022 November 18, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Unicycive Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-283210 Filed November 13, 2024 Ladies and Gentlemen: Pursuant |
|
| November 14, 2024 |
November 14, 2024 Shalabh Gupta, M.D. Chief Executive Officer Unicycive Therapeutics, Inc. 4300 El Camino Real, Suite 210 Los Altos, CA 94022 Re: Unicycive Therapeutics, Inc. Registration Statement on Form S-3 Filed November 13, 2024 File No. 333-283210 Dear Shalabh Gupta M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 46 |
|
| November 14, 2024 |
UNCY / Unicycive Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2427451d31sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* UNICYCIVE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 90466Y103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this St |
|
| November 14, 2024 |
UNCY / Unicycive Therapeutics, Inc. / Logos Global Management LP Passive Investment SC 13G/A 1 uncy13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Unicycive Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 90466Y103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| November 14, 2024 |
SC 13G/A 1 ea022116107-13ga1vivounicyc.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Unicycive Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 90466Y103 (CUSIP Number) October 9, 2024 (Date of Event Whi |
|
| November 14, 2024 |
Exhibit 1: Joint Filing Agreement EX-99.1 2 tm2427451d31ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissi |
|
| November 14, 2024 |
UNCY / Unicycive Therapeutics, Inc. / GREAT POINT PARTNERS LLC Passive Investment SC 13G/A 1 greatpoint-uncy093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Unicycive Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 90466Y103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statemen |
|
| November 14, 2024 |
SC 13G/A 1 sc13da107422uncy11142024.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Unicycive Therapeutics, Inc. (Name of Issuer) Common Stock, par va |
|
| November 13, 2024 |
Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF CORRECTION Unicycive Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware. DOES HEREBY CERTIFY: 1. The name of the corporation is Unicycive Therapeutics, Inc. 2. That the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stoc |
|
| November 13, 2024 |
UNCY / Unicycive Therapeutics, Inc. / Walleye Capital LLC Passive Investment SC 13G 1 walleye-uncy093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* UNICYCIVE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 90466Y103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check t |
|
| November 13, 2024 |
Exhibit 99.1 Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update – OLC New Drug Application (NDA) Accepted by the FDA with a PDUFA Target Action Date of June 28, 2025– – Commercial Planning in Progress for 2025 Launch – – Late Breaker Poster Presentation on OLC at ASN Kidney Week – – Successful Completion of UNI-494 Phase 1 Trial – LOS ALTOS, Calif., November 13, |
|
| November 13, 2024 |
As filed with the U.S. Securities and Exchange Commission on November 13, 2024 As filed with the U.S. Securities and Exchange Commission on November 13, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Unicycive Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-3638692 (State or other jurisdiction of (I.R.S. Employer incorpora |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40582 UNICYCIVE THERAP |
|
| November 13, 2024 |
Exhibit 4.3 UNICYCIVE THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee’s Certificat |
|
| November 13, 2024 |
As filed with the U.S. Securities and Exchange Commission on November 13, 2024 As filed with the U.S. Securities and Exchange Commission on November 13, 2024 Registration No. 333-266890 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Unicycive Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-3638692 (State or other ju |
|
| November 13, 2024 |
Form of Subordinated Indenture Exhibit 4.4 UNICYCIVE THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Ce |
|
| November 13, 2024 |
Sales Agreement, dated as of November 13, 2024, between the Company and Guggenheim Securities, LLC Exhibit 1.1 Execution Version UNICYCIVE THERAPEUTICS, INC. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT November 13, 2024 Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 Ladies and Gentlemen: Unicycive Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Guggenheim Securities, LLC (the “Agent”), as |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Unicycive Therapeutics, Inc. |
|
| November 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) UNICYCIVE THERAPEUTICS, INC. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2024 Unicycive Therapeutics, Inc. |
|
| November 12, 2024 |
Exhibit 99.1 Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis – FDA sets PDUFA Action Date of June 28, 2025 – Company Preparing for 2025 Commercial Launch – LOS ALTOS, California, November 11, 2024 - Unicycive Therapeutics, Inc. (Nasdaq: |
|
| October 11, 2024 |
UNCY / Unicycive Therapeutics, Inc. / Octagon Capital Advisors LP Passive Investment SC 13G 1 uncy1011241sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Unicycive Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 90466Y103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropr |
|
| September 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2024 Unicycive Therapeutics, Inc. |
|
| August 14, 2024 |
Exhibit 99.1 Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update – On Track to Submit OLC New Drug Application (NDA) by End of August 2024 – LOS ALTOS, Calif., August 14, 2024 – Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced i |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Unicycive Therapeutics, Inc. |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40582 UNICYCIVE THERAPEUTIC |
|
| August 14, 2024 |
Exhibit 10.2 CONFIDENTIAL [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. FIRST Amendment to manufacturing and supply agreement This First Amendment to the Manufacturing and Supply Agreement (this “First Amendment”) is made by and between Unicycive Therapeutics Inc., a Del |
|
| August 14, 2024 |
Exhibit 10.3 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), dated August 12, 2024, is by and among Unicycive Therapeutics Inc., a Delaware corporation (the “Company”), and Doug Jermasek (the “Executive”). WHEREAS, the Company desires to continue to employ Executive, and Executive desires to continue to be employed by, the Company, in each case as of the date written above (the |
|
| August 14, 2024 |
Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. MANUFACTURING AND SUPPLY AGREEMENT This Manufacturing and Supply Agreement, effective as of 31st October 2020 (the “Effective Date”), is entered into by and between Unicycive Therapeutics Inc., a Delaware corpora |
|
| July 18, 2024 |
UNCY / Unicycive Therapeutics, Inc. / GREAT POINT PARTNERS LLC Passive Investment SC 13G 1 greatpoint-uncy071624.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Unicycive Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 90466Y103 (CUSIP Number) July 16, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| July 16, 2024 |
50,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-280703 PROSPECTUS 50,000,000 Shares of Common Stock The selling stockholders named in this prospectus may use this prospectus to offer and resell from time to time up to 50,000,000 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”) of Unicycive Therapeutics, Inc. (referred to in this prospectus as “we,” “us,” |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 Unicycive Therapeutics, Inc. |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 Unicycive Therapeutics, Inc. |
|
| July 11, 2024 |
Unicycive Therapeutics, Inc. 4300 El Camino Real, Suite 210 Los Altos, CA 94022 Unicycive Therapeutics, Inc. 4300 El Camino Real, Suite 210 Los Altos, CA 94022 July 11, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Joshua Gorsky Re: Unicycive Therapeutics, Inc. Registration Statement on Form S-3 File No. 333- 280703 Filed July 5, 2024 Ladies and Gentlemen: Pursuant to Rule 4 |
|
| July 8, 2024 |
July 8, 2024 Shalabh Gupta Chief Executive Officer Unicycive Therapeutics, Inc. 4300 El Camino Real, Suite 210 Los Altos, CA 94022 Re: Unicycive Therapeutics, Inc. Registration Statement on Form S-3 Filed July 5, 2024 File No. 333-280703 Dear Shalabh Gupta: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding r |
|
| July 5, 2024 |
As filed with the U.S. Securities and Exchange Commission on July 5, 2024 As filed with the U.S. Securities and Exchange Commission on July 5, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 UNICYCIVE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 81-3638692 (State or other jurisdiction of (I.R.S. Employer incorporation |
|
| July 5, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Unicycive Therapeutics, Inc. |
|
| July 2, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 Unicycive Therapeutics, Inc. |
|
| June 26, 2024 |
Exhibit 3.1 |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 Unicycive Therapeutics, Inc. |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 Unicycive Therapeutics, Inc. |
|
| June 25, 2024 |
Exhibit 99.1 Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial – Successfully Established Favorable Tolerability and Safety of OLC – – New Drug Application (NDA) Submission Anticipated in Q3 2024 – – Webcast and Conference Call Today at 8:30 A.M. ET – LOS ALTOS, California, June 25, 2024 - Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical- |
|
| June 25, 2024 |
Exhibit 99.2 Oxylanthanum Carbonate (OLC) UNI - OLC - 201 Pivotal Trial Topline Data June 25, 2024 NASDAQ: UNCY Forward Looking Statements This presentation contains certain “forward - looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Ac t of 1995. All statements, other than statements of historical or present facts, are forward - |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 Unicycive Therapeutics, Inc. |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40582 UNICYCIVE THERAPEUTI |
|
| May 13, 2024 |
Exhibit 99.1 Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update – On Track to Provide Topline Data from the Ongoing Pivotal Clinical Trial with Oxylanthanum Carbonate (OLC) in Q2 2024 – – Multiple Presentations on OLC and UNI-494 at Prominent, Upcoming Medical Meetings – LOS ALTOS, Calif., May 13, 2024 – Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Unicycive Therapeutics, Inc. |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stateme |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40582 UNICYCIVE THERAPEUTICS, INC. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 29, 2024 |
Exhibit 99.1 Unicycive Announces Full Year 2023 Financial Results and Provides Business Update – Oxylanthanum Carbonate (OLC) Topline Data Expected in Q2 2024 – – UNI-494 Granted Orphan Drug Designation in Delayed Graft Function of Acute Kidney Injury – – UNI-494 Phase 1 Single Ascending Dose Portion of Clinical Trial Complete – LOS ALTOS, Calif., March 28, 2024 – Unicycive Therapeutics, Inc. (Nas |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Unicycive Therapeutics, Inc. |
|
| March 28, 2024 |
Exhibit 97.1 Unicycive Therapeutics, Inc. CLAWBACK POLICY I. Purpose and Scope The Board of Directors (the “Board”) of the Company believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted th |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40582 UNICYCIVE THERAPEUTICS, INC. |
|
| March 14, 2024 |
Certificate of Elimination of Series A-5 Convertible Preferred Stock Exhibit 3.5 CERTIFICATE OF ELIMINATION OF Series a-5 Convertible Preferred STock OF unicycive Therapeutics, Inc. (Pursuant to Section 151(g) of the Delaware General Corporation Law) unicycive Therapeutics, Inc., a Delaware corporation (the “Corporation”) does hereby certify that the following resolutions were duly adopted by the Corporation’s Board of Directors: Resolved, that no shares of the Cor |
|
| March 14, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 13, 2024, by and among Unicycive Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and each |
|
| March 14, 2024 |
Exhibit 3.6 UNICYCIVE THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE VOTING PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW UNICYCIVE THERAPEUTICS, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation La |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 UNICYCIVE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40582 81-3638692 (State or other jurisdiction of incorporation) (Commis |
|
| March 14, 2024 |
Exhibit 10.1 Exchange agreement This Exchange Agreement (this “Agreement”) is made as of March 13, 2024, by and among Unicycive Therapeutics, Inc., a Delaware corporation (the “Company”), and the holder of shares of Series A Preferred Stock (as defined in the Current Charter) listed on Exhibit A attached hereto (such shares the “Surrendered Shares” and the holder, the “Exchanging Holder”). RECITAL |
|
| March 14, 2024 |
Certificate of Elimination of Series A-1 Convertible Preferred Stock Exhibit 3.1 CERTIFICATE OF ELIMINATION OF Series a-1 Convertible Preferred STock OF unicycive Therapeutics, Inc. (Pursuant to Section 151(g) of the Delaware General Corporation Law) unicycive Therapeutics, Inc., a Delaware corporation (the “Corporation”) does hereby certify that the following resolutions were duly adopted by the Corporation’s Board of Directors: Resolved, that no shares of the Cor |
|
| March 14, 2024 |
Certificate of Elimination of Series A-2 Convertible Preferred Stock Exhibit 3.2 CERTIFICATE OF ELIMINATION OF Series a-2 Convertible Preferred STock OF unicycive Therapeutics, Inc. (Pursuant to Section 151(g) of the Delaware General Corporation Law) unicycive Therapeutics, Inc., a Delaware corporation (the “Corporation”) does hereby certify that the following resolutions were duly adopted by the Corporation’s Board of Directors: Resolved, that no shares of the Cor |
|
| March 14, 2024 |
Exhibit 3.1 UNICYCIVE THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW UNICYCIVE THERAPEUTICS, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby c |
|
| March 14, 2024 |
Exhibit 4.2 UNICYCIVE THERAPEUTICS, INC. AMENDED AND RESTATED TRANCHE B WARRANT TO PURCHASE SERIES A-4 PREFERRED STOCK Warrant No.: A- Number of Warrant Shares: Date of Issuance: March 13, 2024 (“Issuance Date”) Expiration Date: Twenty-one (21) days following the Company’s announcement of receipt of FDA approval for Renazorb (“Expiration Date”) Unicycive Therapeutics, Inc., a Delaware corporation |
|
| March 14, 2024 |
Exhibit 99.1 Unicycive Announces $50 Million Private Placement Unicycive Therapeutics, Inc. Thu, Mar 14, 2024, 4:03 AM PDT Unicycive Therapeutics, Inc. Led by new investors Octagon Capital and Great Point Partners, LLC, with participation from new and existing investors including Logos Capital, Nantahala Capital, SilverArc Capital, Velan Capital, Vivo Capital and Walleye Capital LOS ALTOS, Calif., |
|
| March 14, 2024 |
Certificate of Elimination of Series A-4 Convertible Preferred Stock Exhibit 3.4 CERTIFICATE OF ELIMINATION OF Series a-4 Convertible Preferred STock OF unicycive Therapeutics, Inc. (Pursuant to Section 151(g) of the Delaware General Corporation Law) unicycive Therapeutics, Inc., a Delaware corporation (the “Corporation”) does hereby certify that the following resolutions were duly adopted by the Corporation’s Board of Directors: Resolved, that no shares of the Cor |
|
| March 14, 2024 |
Form of Amended and Restated Tranche A Warrant Exhibit 4.1 UNICYCIVE THERAPEUTICS, INC. AMENDED AND RESTATED TRANCHE A WARRANT TO PURCHASE SERIES A-3 PREFERRED STOCK Warrant No.: A- Number of Warrant Shares: Date of Issuance: March 13, 2024 (“Issuance Date”) Expiration Date: Twenty-one (21) days following the Company’s announcement of receipt of FDA approval for Renazorb (“Expiration Date”) Unicycive Therapeutics, Inc., a Delaware corporation |
|
| March 14, 2024 |
Certificate of Elimination of Series A-3 Convertible Preferred Stock Exhibit 3.3 CERTIFICATE OF ELIMINATION OF Series a-3 Convertible Preferred STock OF unicycive Therapeutics, Inc. (Pursuant to Section 151(g) of the Delaware General Corporation Law) unicycive Therapeutics, Inc., a Delaware corporation (the “Corporation”) does hereby certify that the following resolutions were duly adopted by the Corporation’s Board of Directors: Resolved, that no shares of the Cor |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 UNICYCIVE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40582 81-3638692 (State or other jurisdiction of incorporation) (Commis |
|
| March 14, 2024 |
Exhibit 4.3 UNICYCIVE THERAPEUTICS, INC. AMENDED AND RESTATED TRANCHE C WARRANT TO PURCHASE SERIES A-5 PREFERRED STOCK Warrant No.: A- Number of Warrant Shares: Date of Issuance: March 13, 2024 (“Issuance Date”) Expiration Date: Twenty-one (21) days following the Company’s announcement of receipt of FDA approval for Renazorb (“Expiration Date”) Unicycive Therapeutics, Inc., a Delaware corporation |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 Unicycive Therapeutics, Inc. |
|
| February 14, 2024 |
Exhibit 1: Joint Filing Agreement EX-99.1 2 tm246065d29ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio |
|
| February 14, 2024 |
UNCY / Unicycive Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
UNCY / Unicycive Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246065d29sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* UNICYCIVE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 90466Y103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Stat |
|
| February 14, 2024 |
SC 13G/A 1 tm243309d31sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* UNICYCIVE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 90466Y103 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statem |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* UNICYCIVE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 90466Y103 (CUSIP Number) September 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| January 22, 2024 |
UNCY / Unicycive Therapeutics, Inc. / Logos Global Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Unicycive Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 90466Y103 (CUSIP Number) June 26, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| December 8, 2023 |
As filed with the Securities and Exchange Commission on December 8, 2023 As filed with the Securities and Exchange Commission on December 8, 2023 Registration No. |
|
| December 8, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) UNICYCIVE THERAPEUTICS, INC. |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40582 UNICYCIVE THERAP |
|
| November 14, 2023 |
Exhibit 99.1 Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update Reached Alignment with the FDA on the Data Package Requirements to File NDA for oxylanthanum carbonate (OLC) OLC Pivotal Clinical Trial Expected to Initiate Before Year End LOS ALTOS, Calif., November 14, 2023 - Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-st |
|
| November 14, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Unicycive Therapeutics, Inc. |
|
| October 23, 2023 |
Exhibit 99.1 Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC) - Pivotal clinical trial expected to initiate before year end - LOS ALTOS, California, October 23, 2023 - Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “U |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2023 Unicycive Therapeutics, Inc. |
|
| September 25, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 Unicycive Therapeutics, Inc. |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 Unicycive Therapeutics, Inc. |
|
| September 6, 2023 |
Exhibit 99.1 Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD - Appointment adds decades of drug development experience from a seasoned executive – LOS ALTOS, California, September 6, 2023 - Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unic |
|
| August 31, 2023 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2023 Unicycive Therapeutics, Inc. |
|
| August 15, 2023 |
Exhibit 99.1 Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update Recent Data Publications Highlight the Benefits of Oxylanthanum Carbonate (OLC) to Improve Medication Adherence and Quality of Life for Patients with Chronic Kidney Disease Feedback from FDA Expected in Fall 2023 for OLC Program UNI-494 Phase 1 Trial Progressing as Planned with IND Application Expec |
|
| August 15, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Unicycive Therapeutics, Inc. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40582 UNICYCIVE THERAPEUTIC |
|
| August 1, 2023 |
Unicycive Therapeutics, Inc. 4300 El Camino Real, Suite 210 Los Altos, CA 94022 Unicycive Therapeutics, Inc. 4300 El Camino Real, Suite 210 Los Altos, CA 94022 August 1, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Unicycive Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-273221 Filed July 13, 2023 Ladies and Gentlemen: Pursuant to Rule |
|
| July 31, 2023 |
Letter from Mayer Hoffman McCann P.C. dated July 31, 2023 Exhibit 16.1 July 31, 2023 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Commissioners: We have read Item 4.01 of Unicycive Therapeutics, Inc.’s Form 8-K dated July 31, 2023, and we agree with the statements set forth in Item 4.01, insofar as they relate to our firm. We have no basis to agree or disagree with other statements made by the registrant contained in Item 4 |
|
| July 31, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2023 Unicycive Therapeutics, Inc. |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2023 Unicycive Therapeutics, Inc. |
|
| July 19, 2023 |
United States securities and exchange commission logo July 19, 2023 Shalabh Gupta Chief Executive Officer Unicycive Therapeutics, Inc. |
|
| July 14, 2023 |
Exhibit 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Unicycive Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 90466Y103 (CUSIP Number) July 11, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| July 13, 2023 |
As filed with the U.S. Securities and Exchange Commission on July 12, 2023 As filed with the U.S. Securities and Exchange Commission on July 12, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 UNICYCIVE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 81-3638692 (State or other jurisdiction of (I.R.S. Employer incorporation |
|
| July 13, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Unicycive Therapeutics, Inc. |
|
| July 6, 2023 |
UNCY / Unicycive Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Unicycive Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 90466Y103 (CUSIP Numb |
|
| July 6, 2023 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated July 6, 2023 with respect to the Common Stock, $0.001 par value per share, of Unicycive Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance w |
|
| July 6, 2023 |
UNCY / Unicycive Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* UNICYCIVE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 90466Y103 (CUSIP Number) June 26, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| June 30, 2023 |
Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program Exhibit 99.1 Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program LOS ALTOS, California, June 29, 2023 - Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today provided an update based on recent interactions with the U.S. Food and Drug Administrat |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 Unicycive Therapeutics, Inc. |
|
| June 26, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 Unicycive Therapeutics, Inc. |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 Unicycive Therapeutics, Inc. |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 Unicycive Therapeutics, Inc. |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-40582 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐ |
|
| May 16, 2023 |
Exhibit 99.1 Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update Closed on previously announced transformational fundraising that included $30 million financing upfront with up to an additional $100 million tied to the satisfaction of milestones Continued progress with plan to file New Drug Application with the U.S. Food and Drug Administration in Q3 2023, with th |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40582 UNICYCIVE THERAPEUTI |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 տ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40582 UNICYCIVE THERAPEUTICS, INC. |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 10, 2023 |
Exhibit 10.1 AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT This AMENDMENT NO. 1 (“Amendment No. 1”) to the SECURITIES PURCHASE AGREEMENT originally dated as of March 3, 2023 (the “Agreement”), by and among Unicycive Therapeutics, Inc., a Delaware corporation with headquarters located at 4300 El Camino Real, Suite 210, Los Altos, CA 94022 (the “Company”), and the purchasers identified on the sig |
|
| April 10, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2023 Unicycive Therapeutics, Inc. |
|
| March 31, 2023 |
Exhibit 99.1 Unicycive Announces Full Year 2022 Financial Results and Provides Business Update Closed transformational fundraise that included $30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones Financing by new and existing institutional investors from high-profile healthcare-focused funds to support launch and commercialization of investigationa |
|
| March 31, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 Unicycive Therapeutics, Inc. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40582 UNICYCIVE THERAPEUTICS, INC. |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 Unicycive Therapeutics, Inc. |
|
| March 6, 2023 |
Exhibit 10.2 PERSONAL AND CONFIDENTIAL March 3, 2023 Shalabh Gupta, M.D. Chief Executive Officer, President and Chairman Unicycive Therapeutics, Inc. 4300 El Camino Real, Suite 210 Los Altos, CA 94022 Dear Dr. Gupta: This letter (the “Agreement”) constitutes the agreement between EF Hutton, division of Benchmark Investments, LLC (“EF Hutton”, or the “Placement Agent”) and Unicycive Therapeutics, I |
|
| March 6, 2023 |
Exhibit 4.1 |
|
| March 6, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 3, 2023, by and among Unicycive Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and each P |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023 UNICYCIVE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40582 81-3638692 (State or other jurisdiction of incorporation) (Commiss |
|
| March 6, 2023 |
Exhibit 4.4 UNICYCIVE THERAPEUTICS, INC. TRANCHE C WARRANT TO PURCHASE SERIES A-5 PREFERRED STOCK Warrant No.: C- Number of Warrant Shares: Date of Issuance: , 2023 (“Issuance Date”) Expiration Date: Twenty-one (21) days following the Company’s public disclosure of financial results for four (4) quarters of commercial sales of Renazorb following receipt of Transitional Drug Add-On Payment Adjustme |
|
| March 6, 2023 |
Exhibit 3.1 UNICYCIVE THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE VOTING PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW UNICYCIVE THERAPEUTICS, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does h |
|
| March 6, 2023 |
Exhibit 4.3 UNICYCIVE THERAPEUTICS, INC. TRANCHE B WARRANT TO PURCHASE SERIES A-4 PREFERRED STOCK Warrant No.: B- Number of Warrant Shares: Date of Issuance: , 2023 (“Issuance Date”) Expiration Date: Twenty-one (21) days following the Company’s announcement of receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb (“Expiration Date”) Unicycive Therapeutics, Inc., a Delaware c |
|
| March 6, 2023 |
Exhibit 99.1 Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb $30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones Led by Vivo Capital with participation from RA Capital, BVF Partners, Logos Capital, and supported by existing investors Nantahala Capital Partners and Rosalind Advisors Inc |
|
| March 6, 2023 |
Exhibit 4.2 UNICYCIVE THERAPEUTICS, INC. TRANCHE A WARRANT TO PURCHASE SERIES A-3 PREFERRED STOCK Warrant No.: A- Number of Warrant Shares: Date of Issuance: , 2023 (“Issuance Date”) Expiration Date: Twenty-one (21) days following the Company’s announcement of receipt of FDA approval for Renazorb (“Expiration Date”) Unicycive Therapeutics, Inc., a Delaware corporation (the “Company”), certifies th |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Unicycive Therapeutics, Inc. |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* UNICYCIVE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 90466Y103 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 14, 2023 |
UNCY / Unicycive Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-uncy123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* UNICYCIVE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 90466Y103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2023 Unicycive Therapeutics, Inc. |
|
| February 2, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2023 Unicycive Therapeutics, Inc. |
|
| February 2, 2023 |
Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. LICENSE AGREEMENT This License Agreement (this “Agreement”), effective as of February 1, 2023 (the “Effective Date”), is entered into by and between Unicycive Therapeutics Inc., a Delaware corporation having offi |
|
| February 2, 2023 |
Exhibit 99.1 Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea Develops Renazorb opportunity in new market for patients with hyperphosphatemia Agreement includes upfront payment, royalties, and milestone payments LOS ALTOS, Calif., February 2, 2023 - Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company de |
|
| December 29, 2022 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2022 Unicycive Therapeutics, Inc. |
|
| December 29, 2022 |
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock EX-99.1 2 ea170993ex99-1unicycive.htm PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED DECEMBER 29, 2022 Exhibit 99.1 Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock LOS ALTOS, Calif., December 29, 2022 - Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced |
|
| December 28, 2022 |
NASDAQ: UNCY Renazorb: BE Study Update EX-99.2 3 ea170920ex99-2unicycive.htm CORPORATE PRESENTATION OF UNICYCIVE THERAPEUTICS, INC Exhibit 99.2 NASDAQ: UNCY Renazorb: BE Study Update Renazorb Background 2 • Renazorb • Novel lanthanum - based phosphate binder • In development for the treatment of hyperphosphatemia in CKD patients on dialysis • Regulatory Pathway • Agreement with the FDA on acceptability of 505(b)(2) pathway for registra |
|
| December 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2022 Unicycive Therapeutics, Inc. |
|
| December 28, 2022 |
Exhibit 99.1 Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb Renazorb demonstrates pharmacodynamic bioequivalence to Fosrenol Renazorb?s enhanced product profile features reduced pill burden and small, swallowable tablets, which may improve patient compliance On track to file New Drug Application mid-2023 LOS ALTOS, Calif., December 28, 2022 - Unicycive Therapeutics |
|
| November 14, 2022 |
Exhibit 99.1 Press Release Unicycive Announces Third Quarter Financial Results and Provides Business Update Topline results by year-end as enrollment completed for pivotal bioequivalence study of RENAZORB? (lanthanum dioxycarbonate), an investigational phosphate binder for the treatment of hyperphosphatemia in Chronic Kidney Disease (CKD) patients on dialysis On track to file New Drug Application |
|
| November 14, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Unicycive Therapeutics, Inc. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40582 UNICYCIVE THERAP |
|
| August 22, 2022 |
Unicycive Therapeutics, Inc. 4300 El Camino Real, Suite 210 Los Altos, CA 94022 Unicycive Therapeutics, Inc. 4300 El Camino Real, Suite 210 Los Altos, CA 94022 August 22, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Christine Westbrook Re: Unicycive Therapeutics, Inc. Form S-3 File No. 333-266890 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 19 |
|
| August 22, 2022 |
United States securities and exchange commission logo August 22, 2022 Shalabh Gupta, M. |
|
| August 16, 2022 |
Form of Subordinated Indenture Exhibit 4.4 UNICYCIVE THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Ce |
|
| August 16, 2022 |
EX-1.1 2 ea164353ex1-1unicycive.htm CAPITAL ON DEMANDTM SALES AGREEMENT, DATED AS OF AUGUST 15, 2022, BETWEEN THE COMPANY AND JONESTRADING INSTITUTIONAL SERVICES LLC Exhibit 1.1 UNICYCIVE THERAPEUTICS, INC. Common Stock ($0.001 par value per share) Capital on Demand™ Sales Agreement August 15, 2022 JonesTrading Institutional Services LLC 211 East 43rd Street, 15th Floor New York, NY 10017 Ladies a |
|
| August 16, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) UNICYCIVE THERAPEUTICS, INC. |
|
| August 16, 2022 |
As filed with the U.S. Securities and Exchange Commission on August 15, 2022 As filed with the U.S. Securities and Exchange Commission on August 15, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Unicycive Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-3638692 (State or other jurisdiction (I.R.S. Employer of incorporati |
|
| August 16, 2022 |
Exhibit 4.3 UNICYCIVE THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee?s Certificat |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 Unicycive Therapeutics, Inc. |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40582 UNICYCIVE THERAPEUTIC |
|
| August 15, 2022 |
Exhibit 99.1 Press Release Unicycive Announces Second Quarter Financial Results and Provides Business Update Advancing global commercial strategy for Renazorb to treat hyperphosphatemia On track to file regulatory submission to initiate Phase 1 healthy volunteer study with UNI-494 in second half of 2022 LOS ALTOS, Calif., August 15, 2022 - Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical st |
|
| August 8, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 Unicycive Therapeutics, Inc. |
|
| July 18, 2022 |
Exhibit 99.1 Press Release Unicycive Announces Exclusive License and Development Agreement with Lee?s Pharmaceutical Holdings Limited for Renazorb in China and Certain Other Asian Markets Expands and accelerates Renazorb opportunity in important markets for patients with hyperphosphatemia through local partner with deep domain expertise Agreement includes upfront payment, royalties and milestone p |
|
| July 18, 2022 |
Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. LICENSE AGREEMENT This License Agreement (this ?Agreement?), effective as of July 14, 2022 (the ?Effective Date?), is entered into by and between Unicycive Therapeutics, Inc., a Delaware corporation having office |
|
| July 18, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2022 Unicycive Therapeutics, Inc. |
|
| June 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 Unicycive Therapeutics, Inc. |
|
| May 12, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Unicycive Therapeutics, Inc. |
|
| May 12, 2022 |
EX-99.1 2 ea159808ex99-1unicycive.htm PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED MAY 12, 2022 Exhibit 99.1 Press Release Unicycive Announces First Quarter Financial Results and Provides Business Update On track to initiate clinical bioequivalence study of Renazorb to treat hyperphosphatemia in healthy volunteers in second quarter 2022 Plans to initiate Phase 1 study for UNI-494 in second |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40582 UNICYCIVE THERAPEUTI |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 31, 2022 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Unicycive Therapeutics, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): (i) common stock, $0.001 par value per share (?Common Stock?). Unless the context otherwi |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40582 UNICYCIVE THERAPEUTICS, INC. |
|
| March 31, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 Unicycive Therapeutics, Inc. |
|
| March 31, 2022 |
EX-14.1 3 f10k2021ex14-1unicycive.htm CODE OF BUSINESS CONDUCT AND ETHICS Exhibit 14.1 UNICYCIVE THERAPEUTICS, INC. CODE OF BUSINESS CONDUCT AND ETHICS INTRODUCTION Unicycive Therapeutics, Inc., a Delaware corporation (the “Company”) is committed to maintaining the highest standards of business conduct and ethics. This Code of Business Conduct and Ethics (the “Code”) reflects the business practice |
|
| March 31, 2022 |
EX-99.1 2 ea157686ex99-1unicycive.htm PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED MARCH 31, 2022 Exhibit 99.1 Press Release Unicycive Announces Full Year 2021 Financial Results and Provides Business Update On track to initiate clinical bioequivalence study of Renazorb to treat hyperphosphatemia in healthy volunteers in first half of 2022 Plans to initiate Phase 1 study for UNI-494 in secon |
|
| February 15, 2022 |
EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including additional amendments thereto) with respect to the shares of Common Stock, par value $0.001 per share, of Unicycive Therapeutics, Inc. This Joint F |
|
| February 15, 2022 |
UNCY / Unicycive Therapeutics, Inc. / ARMISTICE CAPITAL, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Unicycive Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 90466Y103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 14, 2022 |
EX-1 2 ex-1.htm JOINT ACQUISITION STATEMENT Unicycive Therapeutics, Inc SC 13G/A EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigne |
|
| February 14, 2022 |
UNCY / Unicycive Therapeutics, Inc. / Nantahala Capital Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* UNICYCIVE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 90466Y103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 20, 2022 |
UNCY / Unicycive Therapeutics, Inc. / Rosalind Advisors, Inc. - SC 13G/A Passive Investment SC 13G/A 1 unicycive13ga1.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) Under the Securities Exchange Act of 1934 UNICYCIVE THERAPEUTICS, INC. (Name of Issuer) Common Shares (Title of Class of Securities) 90466Y103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate bo |
|
| January 20, 2022 |
Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of UNICYCIVE THERAPEUTICS, INC. |
|
| November 29, 2021 |
EX-99.1 2 ea151445ex99-1unicycive.htm PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED NOVEMBER 29, 2021 Exhibit 99.1 Unicycive Therapeutics Receives Confirmatory Guidance on Renazorb Regulatory Pathway On-track to submit New Drug Application in Q4 2022 LOS ALTOS, Calif., November 29, 2021 - Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies |
|
| November 29, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2021 Unicycive Therapeutics, Inc. |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2021 Unicycive Therapeutics, Inc. |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40582 UNICYCIVE THERAP |
|
| November 12, 2021 |
EX-99.1 2 ea150418ex99-1unicycive.htm PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED NOVEMBER 11, 2021 Exhibit 99.1 Unicycive Therapeutics Announces Third Quarter 2021 Financial Results Expect to receive confirmatory guidance on Renazorb regulatory pathway from the U.S. Food and Drug Administration in Q4 2021 LOS ALTOS, Calif., November 11, 2021 - Unicycive Therapeutics, Inc. (Nasdaq: UNCY), |
|
| September 23, 2021 |
UNCY / Unicycive Therapeutics, Inc. / Rosalind Advisors, Inc. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 UNICYCIVE THERAPEUTICS, INC. (Name of Issuer) Common Shares (Title of Class of Securities) 90466Y103 (CUSIP Number) September 14, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| September 23, 2021 |
Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of UNICYCIVE THERAPEUTICS, INC. |
|
| September 10, 2021 |
As filed with the Securities and Exchange Commission on September 10, 2021 As filed with the Securities and Exchange Commission on September 10, 2021 Registration No. |
